Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients
Hypertension

About this trial
This is an interventional diagnostic trial for Hypertension focused on measuring hypertension, blood pressure, blood pressure medications, metoprolol, nebivolol, vascular oxidative stress, nitric oxide, nitric oxide synthase (eNOS), endothelium, endothelial dysfunction, endothelial cell protein expression, microvascular blood flow, flow mediated dilation, handgrip exercise, endothelial cell collection, microbubbles, Definity
Eligibility Criteria
Inclusion Criteria:
- Men and women with stage I primary untreated hypertension (BP between 140-159/90-99 mmHg)
- Age 18-65
Exclusion Criteria:
- Congestive heart failure
- Coronary artery disease
- Left ventricular hypertrophy by echocardiography or ECG
- History of stroke
- Average blood pressure >159/99 mmHg
- Bradycardia with a resting heart rate <55 bpm
- Chronic kidney disease with a serum creatinine > 1.4 mg/dL
- Asthma or chronic obstructive pulmonary disease
- Women who are pregnant or planning to become pregnant
- Hypersensitivity to beta blockers, hydrochlorothiazide, or Definity
- Any history of substance abuse (other than tobacco)
- Concomitant drug treatment which raises endogenous nitric oxide levels, including nitrates or phosphodiesterase V inhibitors (Viagra, Levitra)
- History of symptomatic bradycardia or heart block
- Patients with Right-to-left, bidirectional, or transient right-to-left cardiac shunts
- Hypersensitivity to perflutren, blood, blood products or albumin.
Sites / Locations
- UT Southwestern Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Initial treatment with metoprolol
Initial treatment with nebivolol
The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.